⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNGX News
Soligenix, Inc. Common Stock
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
prnewswire.com
SNGX
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
prnewswire.com
SNGX
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease
globenewswire.com
SNGX
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
globenewswire.com
SNGX
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
globenewswire.com
SNGX
AMGN
FOLD
CTOR
TNXP
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
globenewswire.com
SNGX
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
globenewswire.com
SNGX
PFE
MRK
BMY
INSM
Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight
prnewswire.com
SNGX
IPH
PFE
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
prnewswire.com
SNGX